NOV 08, 2018 09:00 AM PST

Influenza 2018-2019: Are you ready?

SPONSORED BY: DiaSorin Molecular
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Medical Director - Pediatrics, PRA Health Sciences
    Biography
      Jay M. Lieberman, M.D. is a graduate of Princeton University and the New York University School of Medicine. He is a specialist in pediatric infectious diseases, having completed his residency training in pediatrics at Children's Hospital of Los Angeles and fellowship training in pediatric infectious diseases at Children's Hospital of Los Angeles and at Harbor-UCLA Medical Center.

      Dr. Lieberman joined PRA Health Sciences as a Medical Director in 2017 after 4 years as a Regional Medical Director for Merck Vaccines. Before joining Merck, he was Medical Director of Infectious Diseases at Quest Diagnostics and Laboratory Director for Focus Diagnostics, an infectious diseases reference laboratory owned by Quest.

      Before joining Quest in 2007, Dr. Lieberman was professor of clinical pediatrics at the University of California, Irvine (UCI) and chief of infectious diseases at Miller Children's Hospital in Long Beach. While there, he was the recipient of the Golden Apple Teaching Award from the UCI School of Medicine seven times and the Faculty Teaching Award from Miller Children's Hospital four times.

      His clinical research activities included the evaluation of vaccines, other biologics, and antimicrobials in children. He has published articles on a wide variety of infectious disease topics and was frequently an invited lecturer at national and international meetings.

    Abstract:

    DATE: November 8, 2018
    TIME:  9:00AM PST

    Annual epidemics of influenza place a substantial burden on the health of people in the United States. CDC estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010.

    The cornerstone of influenza prevention is routine annual influenza vaccination, which is recommended for all persons aged ≥6 months who do not have contraindications. Multiple different vaccine types are available, including inactivated, live attenuated, and recombinant vaccines, as well as high dose and adjuvanted inactivated versions.

    The majority of currently circulating influenza viruses are susceptible to the neuraminidase inhibitor antiviral medications—oseltamivir, zanamivir and peramivir. Antiviral treatment with a neuraminidase inhibitor is recommended as early as possible for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at increased risk for influenza-related complications.

    Appropriate treatment of patients with influenza depends on accurate and timely diagnosis, and early diagnosis can reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy. Diagnostic tests available for influenza include viral culture, serology, rapid antigen testing, reverse transcription PCR, immunofluorescence assays, and rapid molecular assays. Molecular assays are increasingly becoming the diagnostic tests of choice.

     

    Learning Objectives:

    • Describe the epidemiology and clinical impact of seasonal influenza
    • Understand strategies for prevention of influenza including current vaccine recommendations
    • Recognize the value of diagnostic testing including advantages and disadvantages of different assay types

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    Loading Comments...
    Show Resources